News | EP Mapping and Imaging Systems | January 28, 2019

Acutus AcQMap Imaging System Helps Eliminate Arrhythmia With Single Ablation

Late-breaking UNCOVER-AF trial data reinforces safety and efficacy of non-contact cardiac mapping technology

Acutus AcQMap Imaging System Helps Eliminate Arrhythmia With Single Ablation

January 28, 2019 — Acutus Medical announced 12-month data from the UNCOVER-AF trial investigating the use of the AcQMap advanced cardiac imaging and mapping visualization system in persistent atrial fibrillation (AF) ablation procedures. Results presented at the 24th Annual AF Symposium, Jan. 24-26 in Boston, show the use of AcQMap resulted in 72.5 percent single-procedure freedom from AF at 12 months. Rigorous post-ablation monitoring showed 89.6 percent of the single-procedure patients experienced zero episodes of AF.

Atrial fibrillation is the most common supraventricular cardiac arrhythmia, affecting more than 33 million people globally.1,2 AF can lead to increased risk of stroke and heart failure, contributing to an estimated 130,000 deaths annually in the United States.3 Cardiac ablation treatment can be effective in reducing AF burden and improving quality of life for patients. However, long-term freedom from AF is achieved in as few as 50 percent of patients who undergo an ablation procedure, often making repeat procedures necessary.4

"We have mapped arrhythmias with the same technology for decades without asking if there's a better way to locate ablation targets and deliver a more precise, patient-specific therapy," said principal investigator Atul Verma, M.D., Ontario, Canada. "The results of the UNCOVER-AF trial demonstrate that with better imaging, we can perform patient-centric ablations with great success, while dramatically improving patient quality of life. This advanced cardiac imaging system paints a complete, high-definition picture in real time and is an important step in advancing the standard of care for AF ablation procedures."

UNCOVER-AF is the first trial to investigate the use of AcQMap to guide ablation therapy in a prospective study of persistent atrial fibrillation. Using AcQMap and a variety of on-market ablation technologies, investigators treated a total of 127 patients with de novo, persistent AF at 13 sites in Europe and Canada using an iterative, adaptive therapeutic approach. In 98 percent of patients, sinus rhythm was achieved at the end of the procedure. Freedom from AF after one or two procedures occurred in 93 percent of patients and 82.4 percent of patients experienced zero AF episodes in the 12 months following. Cleared by the U.S. Food and Drug Administration (FDA) in 2017, AcQMap is the only ultrasound and non-contact cardiac imaging system available for use, according to the company. The AcQMap system received CE marking in 2016.

AcQMap combines proprietary charge mapping and high-resolution ultrasound imaging to create animated, three-dimensional images in seconds that display precise anatomy and atrial arrhythmias. With AcQMap, physicians can create a full-chamber, 360-degree look at the atrium in real time for each individual patient, enabling customized treatment for every case using an iterative map, ablate, re-map, ablate strategy.

For more information:


1. Staerk L, Sherer JA, Ko D, et al. Atrial Fibrillation. Circ Res 2017;120:1501-17. DOI: 10.1161/CIRCRESAHA.117.309732.

2. Chugh, S.S., Havmoeller, R., Narayanan, K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circ Feb 25. 2014; 129: 837–847. DOI: 10.1161/CIRCULATIONAHA.113.005119.

3. Centers for Disease Control and Prevention. About multiple cause of death 1999–2011. CDC WONDER Online Database. 2014.

4. Mujović N, Marinković M, Lenarczyk R, Tilz R, Potpara TS. Catheter Ablation of Atrial Fibrillation: An Overview for Clinicians. Adv Ther. 2017;34(8):1897-1917. DOI: 10.1007/s12325-017-0590-z.

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve